ArticleIn vivo (Athens, Greece)
Astragaloside IV Induces Apoptosis, G
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Molecular mechanisms of astragaloside-IV in hepatocellular carcinoma therapy: a systematic review.BMC cancer · 2025Pooled it
- Protective effects of Astragaloside IV on various liver diseases: From chemistry to herbal medicines (Review).International journal of molecular medicine · 2026Review
- Advancement ofChinese herbal medicines · 2026Review
- Astragaloside IV: a potential nemesis for gastric cancer.Frontiers in pharmacology · 2025Review
- Mechanistic insights into the antitumor effects of astragaloside IV and astragalus polysaccharide in digestive system cancers.Frontiers in pharmacology · 2025Review
- Astragaloside IV as a promising therapeutic agent for liver diseases: current landscape and future perspectives.Frontiers in pharmacology · 2025Review
- Preclinical research and potential clinical application of traditional Chinese medicine in cancer treatment: take Astragalus and Dioscorea opposita as an example.Frontiers in pharmacology · 2025Review
- Research Progress on the Anti-Cancer Effects ofMolecules (Basel, Switzerland) · 2024Review
- Astragaloside Ⅳ mediates the effect and mechanism of KPNB1 on biological behavior and tumor growth in prostate cancer.Heliyon · 2024Article
- Astragaloside IV inhibits cell viability and glycolysis of hepatocellular carcinoma by regulating KAT2A-mediated succinylation of PGAM1.BMC cancer · 2024Article
- Astragaloside IV plays a role in reducing radiation-induced liver inflammation in mice by inhibiting thioredoxin-interacting protein/nod-like receptor protein 3 signaling pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Article
- Anticancer effects and mechanisms of astragaloside‑IV (Review).Oncology reports · 2023Review
- Astragaloside IV, as a potential anticancer agent.Frontiers in pharmacology · 2023Review
- Roles and Mechanisms of Astragaloside IV in Combating Neuronal Aging.Aging and disease · 2022Review
- Astragaloside IV Suppresses Hepatic Proliferation in Regenerating Rat Liver after 70% Partial Hepatectomy via Down-Regulation of Cell Cycle Pathway and DNA Replication.Molecules (Basel, Switzerland) · 2021Article
- Molecular mechanisms of astragaloside‑IV in cancer therapy (Review).International journal of molecular medicine · 2021Review
- The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimHepatocellular carcinoma (HCC) is a primary malignancy of the liver and the third leading cause of cancer death worldwide. Although multiple chemotherapies options are available for HCC, chemo-induced toxicity is inevitable during clinical treatment. Therefore, identifying possible adjuvant agents with both liver-protective and antitumor effects is critical. Herbal medicines have chemopreventive and anti-HCC effect, such as Juzen taiho-to and Sho-saiko-to. Astragaloside IV is a compound extracted from the Chinese medical herb Astragalus membranaceus (Fisch.) Bge. with liver protection potential. However, whether astragaloside IV may also possess tumor-inhibitory capability and its underlying mechanism is remaining unknown. MATERIALS AND
methodsViability analysis, cell-cycle analysis, apoptosis analysis, western blotting analysis and invasion trans-well assay were performed to identify tumor-inhibitory potential of astragaloside IV on HCC cells (SK-Hep1 and Hep3B cells).
resultsWe found that astragaloside IV may induce cytotoxicity and extrinsic/intrinsic apoptosis effect, but also trigger G
conclusionAstragaloside IV effectively suppressed HCC cell proliferation, invasion and anti-apoptosis in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.